View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
December 13, 2021

Pfizer-Sangamo’s therapy shows control of bleeding in haemophilia trial

Giroctocogene fitelparvovec was well-tolerated in the trial with one subject experiencing hypotension and fever. 

Pfizer and Sangamo Therapeutics have reported updated follow-up results from the Phase I/II Alta clinical trial where its experimental gene therapy, giroctocogene fitelparvovec, demonstrated sustained bleeding control in moderately severe to severe haemophilia A patients.

Giroctocogene fitelparvovec is currently being developed in partnership under an international development and marketing agreement between the two companies.

Pfizer obtained the production technology and the Investigational New Drug (IND) application for gene therapy from Sangamo in 2019.

The open-label, multicentre, dose-ranging trial analysed the safety and tolerability of giroctocogene fitelparvovec in individuals with severe haemophilia A.

Findings showed that the five subjects in the highest dose 3e13vg/kg arm were found to have a mean factor VIII (FVIII) activity of 25.4% at 104 weeks.

A mean annualised bleeding rate (ABR) of 0.0 and 1.4 was reported in these subjects in the first year after dosage infusion and during the follow-up period, respectively.

Furthermore, all the events of bleeding happened after week 69 following infusion.

Two individuals had bleeding episodes that required the use of exogenous FVIII without any subjects in the highest dose arm resuming prophylaxis.

In the trial, giroctocogene fitelparvovec was found to be well-tolerated with one subject in the highest dose arm experiencing a treatment-associated serious adverse event of hypotension and fever.

Across all four cohorts, 26 treatment-related adverse events without any cases of FVIII inhibitor development and thrombotic events were observed.

In 2019, the companies reported interim data from Phase I/II Alta trial of SB-525 to treat severe haemophilia A.

Pfizer Rare Disease senior vice-president and chief scientific officer Seng Cheng said: “These latest results further suggest the potential of this investigational therapy to bring transformational benefit to eligible patients living with severe haemophilia A, if confirmed in ongoing clinical trials.”

Another Phase III AFFINE trial of giroctocogene fitelparvovec in patients with haemophilia A has completed more than half of the subject enrolment target.

This trial is currently under the US Food and Drug Administration (FDA) clinal hold due to reports of FVIII levels exceeding 150% in some subjects who received the treatment.

Haemophilia is a haematological rare disease characterised by a deficiency clotting factor VIII, a protein needed for blood clotting.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena